Analysts Set Regeneron Pharmaceuticals Inc. (REGN) Target Price at $486.79
Shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) have been assigned a consensus rating of “Hold” from the twenty-six analysts that are presently covering the company. One research analyst has rated the stock with a sell recommendation, thirteen have issued a hold recommendation and eleven have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $486.79.
Several equities analysts recently weighed in on REGN shares. Goldman Sachs Group Inc. reiterated a “buy” rating and issued a $521.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 27th. Jefferies Group reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 17th. Vetr downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $419.76 price target on the stock. in a report on Monday, July 11th. Roth Capital reiterated a “buy” rating and issued a $520.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday. Finally, Zacks Investment Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $472.00 price target on the stock in a report on Tuesday, August 9th.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 373.47 on Monday. The stock’s 50 day moving average is $399.99 and its 200 day moving average is $392.12. Regeneron Pharmaceuticals has a 52-week low of $329.09 and a 52-week high of $592.59. The company has a market cap of $39.08 billion, a PE ratio of 58.26 and a beta of 1.31.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.65 by $0.17. Regeneron Pharmaceuticals had a net margin of 15.65% and a return on equity of 23.77%. The firm had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.24 billion. During the same quarter in the prior year, the company posted $2.89 earnings per share. The company’s revenue for the quarter was up 21.4% compared to the same quarter last year. Equities analysts forecast that Regeneron Pharmaceuticals will post $11.02 EPS for the current year.
In related news, Director Joseph L. Goldstein sold 2,125 shares of the firm’s stock in a transaction dated Friday, July 29th. The stock was sold at an average price of $425.00, for a total transaction of $903,125.00. Following the completion of the sale, the director now directly owns 15,125 shares of the company’s stock, valued at approximately $6,428,125. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 10.40% of the company’s stock.
Several hedge funds have recently modified their holdings of the company. IFP Advisors Inc increased its stake in shares of Regeneron Pharmaceuticals by 32.3% in the second quarter. IFP Advisors Inc now owns 328 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 80 shares during the last quarter. Advisory Services Network LLC increased its stake in shares of Regeneron Pharmaceuticals by 5,433.3% in the second quarter. Advisory Services Network LLC now owns 332 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 326 shares during the last quarter. Fuller & Thaler Asset Management Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $140,000. Brave Asset Management Inc acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $157,000. Finally, Bessemer Group Inc. increased its stake in shares of Regeneron Pharmaceuticals by 45.4% in the first quarter. Bessemer Group Inc. now owns 548 shares of the biopharmaceutical company’s stock worth $198,000 after buying an additional 171 shares during the last quarter. 68.16% of the stock is owned by hedge funds and other institutional investors.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.
Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.